Want to see HK:6821 full AI Analyst Report?
6821 Stock Chart & Stats
HK$131.00
HK$2.70(2.34%)
At close: 4:00 PM EDT
HK$131.00
HK$2.70(2.34%)
Day’s Range― - ―
52-Week RangeHK$69.20 - HK$178.00
Previous CloseN/A
Volume591.20K
Average Volume (3M)697.27K
Market Cap
HK$63.92B
Enterprise ValueHK$31.73B
Total Cash (Recent Filing)HK$6.61B
Total Debt (Recent Filing)HK$514.12M
Price to Earnings (P/E)52.5
Beta0.86
Next Earnings
Apr 01, 2027Next Dividend Ex-DateN/A
Dividend Yield1.12%
Share Statistics
EPS (TTM)2.90
Shares Outstanding27,834,510
10 Day Avg. Volume553,214
30 Day Avg. Volume697,269
Financial Highlights & Ratios
PEG Ratio1.08
Price to Book (P/B)1.29
Price to Sales (P/S)3.40
P/FCF Ratio165.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$151.28Price Target Upside15.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)4.38
Revenue Forecast (FY)HK$9.44B
Bulls Say, Bears Say
Bulls Say
Sharp Revenue ReboundThe sharp TTM revenue rebound indicates strong recent demand for the company’s outsourced development and manufacturing services. If sustained, higher activity can improve customer engagement, support capacity utilization, and create a broader base for future commercial-stage contracts.
Very Low LeverageExtremely low leverage gives the company substantial financial flexibility and limits interest-related pressure on operations. Its large equity base can support continued investment in pharmaceutical services while improving resilience if customer demand or profitability becomes less favorable.
Solid Operating Cash FlowStrong operating cash generation shows that the core business is producing meaningful cash despite recent investment needs. This supports ongoing operations and strategic spending, while providing a stronger internal funding base than a business dependent primarily on external financing.
Bears Say
Margin CompressionProfitability has materially weakened from the 2022–2023 peak even as revenue rebounded. Lower gross and net margins can reduce the earnings benefit of additional volume, indicate a less favorable business mix, and constrain the durability of near-term profit growth.
Negative Free Cash FlowNegative TTM free cash flow means reported operating profits are not currently translating into surplus cash after investment spending. If this persists, the company may have less internally generated funding for expansion and may experience greater sensitivity to working-capital or capital-expenditure demands.
Lower Returns On EquityThe decline in return on equity indicates that the company is generating less profit from its substantial equity base than in earlier periods. This points to reduced capital efficiency and suggests that balance-sheet strength has not yet translated into a comparable recovery in shareholder returns.
Asymchem Laboratories (Tianjin) Co., Ltd. Class H News
6821 FAQ
What was Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s price range in the past 12 months?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H lowest stock price was HK$69.20 and its highest was HK$178.00 in the past 12 months.
What is Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s market cap?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s market cap is HK$63.92B.
When is Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s upcoming earnings report date?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s upcoming earnings report date is Apr 01, 2027 which is in 160 days.
How were Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s earnings last quarter?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H released its earnings results on Oct 22, 2026. The company reported HK$1.069 earnings per share for the quarter, beating the consensus estimate of HK$0 by HK$1.069.
Is Asymchem Laboratories (Tianjin) Co., Ltd. Class H overvalued?
According to Wall Street analysts Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s price is currently Undervalued.
Does Asymchem Laboratories (Tianjin) Co., Ltd. Class H pay dividends?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H pays a Annually dividend of HK$1.495 which represents an annual dividend yield of 1.12%. See more information on Asymchem Laboratories (Tianjin) Co., Ltd. Class H dividends here
What is Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s EPS estimate?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s EPS estimate is 0.
How many shares outstanding does Asymchem Laboratories (Tianjin) Co., Ltd. Class H have?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H has 27,834,510 shares outstanding.
What happened to Asymchem Laboratories (Tianjin) Co., Ltd. Class H’s price movement after its last earnings report?
Asymchem Laboratories (Tianjin) Co., Ltd. Class H reported an EPS of HK$1.069 in its last earnings report, beating expectations of HK$0. Following the earnings report the stock price went down -7.262%.
Which hedge fund is a major shareholder of Asymchem Laboratories (Tianjin) Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:6821
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Asymchem Laboratories (Tianjin) Co., Ltd. Class H Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$151.28 (15.48% Upside)
HK$151.28 (15.48% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
49.32%
12-Months-Change
Fundamentals
Return on Equity
5.86%
Trailing 12-Months
Asset Growth
10.90%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
Asymchem Laboratories (Tianjin) Co., Ltd. functions as a Contract Development and Manufacturing Organization (CDMO), offering its services to clients across Mainland China and internationally. The company delivers extensive drug research, development, and manufacturing solutions specifically tailored for pharmaceutical and biotechnology enterprises. Their offerings are comprehensive, covering the entire lifecycle from early clinical stages through to full commercialization, including R&D and cGMP compliant production of advanced intermediates, active pharmaceutical ingredients (APIs), and finished formulations, alongside clinical research support. Furthermore, Asymchem engages in pharmaceutical analysis and testing, the sale and distribution of medicinal products, and active participation in pharmaceutical science and technology innovation. The company was founded in 1999 and maintains its headquarters in Tianjin, China.
Asymchem Laboratories (Tianjin) Co., Ltd. Class H (6821) Earnings & Revenues
6821 Stock 12 Month Forecast
Average Price Target
HK$151.28
▲(15.48% Upside)
Technical Analysis
Genscript Biotech
―
Wuxi Biologics (Cayman)
―
Pharmaron Beijing Co., Ltd. Class H
―
Frontage Holdings Corp.
―
Viva Biotech Holdings
―